melatonin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on serious adverse event incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“In terms of safety, no serious adverse events were reported with either melatonin or placebo.”
Quoted verbatim from Effect of melatonin versus placebo for the prevention of delirium among medically hospitalised older patients: a double-blinded randomised controlled trial (project RESTORE).. - Study
- RCT
- Duration
- 5 days
- Dose
- 5 mg or 8 mg oral melatonin nightly for up to 5 days (arms pooled)
- Population
- medically hospitalised patients aged 65 years and over; safety endpoint, ITT
Effect of melatonin versus placebo for the prevention of delirium among medically hospitalised older patients: a double-blinded randomised controlled trial (project RESTORE).2026PMID:41592826Permalink
Keep reading
- Everything the graph holds on melatonin
- Every compound studied against Serious adverse event incidence
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M0Q0919D1AS68NQR0MHFPX25